BIENAIME JEAN JACQUES purchased $112K of ASND
BIENAIME JEAN JACQUES purchased 500 shares of Ascendis Pharma A/S (ASND) at an average of $223.12 ($222.30–$223.76, $0.11M total) across 3 trades on 2026-05-29.
How this was made
The 30-second read
Why it matters
The director's purchase adds a modest positive signal but is unlikely to move the stock significantly.
Market read
Primary relevance is to ASND shareholders; minimal broader market impact.
What to watch
Potential upcoming clinical milestones could be driving the purchase.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Jean Jacques Bienaime purchased 500 shares for $111,562 on 2026-05-29, increasing his holding to 900 shares.
likely slight upward pressure as market prices in insider purchase
Purchase size is modest relative to market cap, but director involvement adds credibility.
Market effects
None significant; insider activity is company‑specific.
No broader regional effect.
Limited to Ascendis Pharma investors.
Counterpoint
Insider purchase may be routine portfolio rebalancing, not a strong bullish signal.
Key entities
- CompanyAscendis Pharma A/S
Biopharmaceutical company listed on Nasdaq under ASND.
- InsiderJean Jacques Bienaime
Director of Ascendis Pharma.
